GlassScriptPhysician profile
Hrishikesh Samant
NPI 1982087755
$80,868.97
in general payments reported to CMS, 2019-2025
23 companies · $65K in 2025
The $65K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $407 · 2021: $310 · 2022: $12.20 · 2023: $1,473 · 2024: $12K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Honoraria: $10K · Travel and Lodging: $6,575 · Consulting Fee: $6,232 · Food and Beverage: $3,296 · Education: $77.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,178.25 |
| Honoraria | $10,050.00 |
| Travel and Lodging | $6,575.38 |
| Consulting Fee | $6,232.10 |
| Food and Beverage | $3,295.61 |
| Education | $77.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $39,267.54 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $25,869.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Fujifilm Healthcare Americas Corporation | $3,810.44 | 2024 | Utaswako Afp-L3 |
| Mirum Pharmaceuticals, INC. | $3,413.42 | 2023-2025 | Livmarli |
| Orphalan INC | $3,115.45 | 2024-2025 | Cuvrior |
| Intercept Pharmaceuticals, INC. | $2,259.54 | 2019-2025 | |
| Eton Pharmaceuticals, INC. | $1,024.60 | 2025 | Nitisinone, Betaine Anhydrous, Carglumic Acid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $582.12 | 2019-2025 | Xifaxan |
| Abbvie INC. | $510.28 | 2019-2025 | |
| Gilead Sciences, INC. | $273.14 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.90 | 2019-2021 | |
| Dova Pharmaceuticals | $156.70 | 2019-2021 | |
| Novo Nordisk INC | $147.48 | 2025 | Wegovy |
| Eisai INC. | $77.00 | 2023 | |
| Pfizer INC. | $31.09 | 2019-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $29.10 | 2020 | |
| Sanofi-Aventis U.S. LLC | $23.65 | 2021 | |
| Daiichi Sankyo INC. | $22.46 | 2021 | |
| Olympus America INC. | $22.45 | 2024 | Evis Exera III Colonovideoscope |
| Dynavax Technologies Corporation | $15.47 | 2019 | |
| Janssen Biotech, INC. | $14.06 | 2023 | Stelara |
| Medtronic, INC. | $12.20 | 2022 | |
| Merck Sharp & Dohme LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hrishikesh Samant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.